Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$23 Mln
P/E Ratio
--
P/B Ratio
2.51
Industry P/E
--
Debt to Equity
0.23
ROE
-1.54 %
ROCE
-35.23 %
Div. Yield
0 %
Book Value
0.31
EPS
-0.27
CFO
$-208.76 Mln
EBITDA
$-231.59 Mln
Net Profit
$-234.94 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Durect Corporation (DRRX)
| -6.84 | -17.70 | -16.93 | -13.20 | -47.17 | -48.51 | -29.14 |
|
BSE Sensex*
| 2.10 | 3.88 | 4.40 | 8.34 | 11.78 | 20.18 | 11.16 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Durect Corporation (DRRX)
| 26.87 | -82.95 | -65.05 | -52.17 | -45.53 | 686.59 | -47.41 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial... to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Address: 10240 Bubb Road, Cupertino, CA, United States, 95014-4166 Read more
Co-Founder, CEO, President & Director
Dr. James E. Brown D.V.M.
Co-Founder, CEO, President & Director
Dr. James E. Brown D.V.M.
Headquarters
Cupertino, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Durect Corporation (DRRX) stood at $ 18 Mln as on 31-Dec-24
The share price of Durect Corporation (DRRX) is $0.70 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Durect Corporation (DRRX) has given a return of -47.17% in the last 3 years.
Durect Corporation (DRRX) has a market capitalisation of $ 23 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Durect Corporation (DRRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Durect Corporation (DRRX) and enter the required number of quantities and click on buy to purchase the shares of Durect Corporation (DRRX).
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Address: 10240 Bubb Road, Cupertino, CA, United States, 95014-4166
The CEO & director of Dr. James E. Brown D.V.M.. is Durect Corporation (DRRX), and CFO & Sr. VP is Dr. James E. Brown D.V.M..
There is no promoter pledging in Durect Corporation (DRRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Durect Corporation (DRRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-68.52
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-409.85
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Durect Corporation (DRRX) was $0 Mln.
$-0.03
(
